Literature DB >> 7821393

Axonal transport of endogenous nerve growth factor (NGF) and NGF receptor in experimental diabetic neuropathy.

R Hellweg1, G Raivich, H D Hartung, C Hock, G W Kreutzberg.   

Abstract

There is increasing evidence that deprivation of the retrogradely transported neurotrophic protein nerve growth factor (NGF) accounts for some functional deficits known to occur in experimental diabetic neuropathy. Here we have studied changes in the axonal transport of endogenous NGF, NGF receptor (NGFR), and NGFR saturation (NGF/NGFR ratio) in the rat sciatic nerve after 2 months of streptozotocin (STZ)-induced diabetes mellitus. Compared with vehicle-treated control rats (blood glucose: 6-12 mM), there was a very clear reduction in the retrograde transport of NGF by 50% (P < 0.001) in STZ-treated, diabetic animals (blood glucose: 33-62 mM). No significant reduction in NGF axonal transport was observed in a subpopulation of STZ-treated rats (poor responders) with nearly normal glucose levels (range: 9-12 mM). No change was observed in any group in the retrograde transport of NGFR. Compared with control rats, however, the apparent NGFR saturation was reduced by 45% (P < 0.002) in STZ diabetics, whereas no change in NGFR saturation was observed in the STZ-poor responders. Moreover, the NGFR saturation and amount of retrogradely transported NGF were negatively correlated to the individual glucose concentration in diabetics (r2 = 0.47 and 0.55, respectively; P < 0.0001). These findings indicate that, while NGFR expression is normal in the STZ-diabetic neuropathy model, the marked decrease in receptor saturation observed in diabetics may reflect low peripheral NGF levels, which in consequence leads to the apparent deprivation of neuronal NGF in diabetic rats.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7821393     DOI: 10.1006/exnr.1994.1181

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  25 in total

1.  Novel systems for in vivo monitoring and microenvironmental investigations of diabetic neuropathy in a murine model.

Authors:  Sharon Amit; Avraham Yaron
Journal:  J Neural Transm (Vienna)       Date:  2012-05-17       Impact factor: 3.575

2.  Human Umbilical Cord Mesenchymal Stem Cells Overexpressing Nerve Growth Factor Ameliorate Diabetic Cystopathy in Rats.

Authors:  Wu WenBo; Zhang Fei; Du YiHeng; Wang Wei; Yan TingMang; Zhou WenHao; Liu QianRu; Liu HaiTao
Journal:  Neurochem Res       Date:  2017-09-26       Impact factor: 3.996

Review 3.  Diabetic peripheral neuropathy: should a chaperone accompany our therapeutic approach?

Authors:  Kevin L Farmer; Chengyuan Li; Rick T Dobrowsky
Journal:  Pharmacol Rev       Date:  2012-08-10       Impact factor: 25.468

Review 4.  Diabetic neuropathy part 1: overview and symmetric phenotypes.

Authors:  Mamatha Pasnoor; Mazen M Dimachkie; Patricia Kluding; Richard J Barohn
Journal:  Neurol Clin       Date:  2013-03-15       Impact factor: 3.806

5.  Treating small fiber neuropathy by topical application of a small molecule modulator of ligand-induced GFRα/RET receptor signaling.

Authors:  Kristian L Hedstrom; Joshua C Murtie; Kathryn Albers; Nigel A Calcutt; Gabriel Corfas
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-21       Impact factor: 11.205

Review 6.  Physiology in Medicine: neuromuscular consequences of diabetic neuropathy.

Authors:  Matti D Allen; Timothy J Doherty; Charles L Rice; Kurt Kimpinski
Journal:  J Appl Physiol (1985)       Date:  2016-03-17

Review 7.  Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy.

Authors:  Gordon Sloan; Dinesh Selvarajah; Solomon Tesfaye
Journal:  Nat Rev Endocrinol       Date:  2021-05-28       Impact factor: 43.330

8.  Cardiac innervation and sudden cardiac death.

Authors:  Masaki Ieda; Keiichi Fukuda
Journal:  Curr Cardiol Rev       Date:  2009-11

9.  Vascular endothelial growth factor gene transfer for diabetic polyneuropathy.

Authors:  John A Kessler
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

10.  Engineered zinc finger protein-mediated VEGF-a activation restores deficient VEGF-a in sensory neurons in experimental diabetes.

Authors:  Elizabeth J Pawson; Beatriz Duran-Jimenez; Richard Surosky; Heather E Brooke; S Kaye Spratt; David R Tomlinson; Natalie J Gardiner
Journal:  Diabetes       Date:  2009-11-23       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.